Qilu Pharmaceutical's Risperidone Orally Disintegrating Film Receives IND Approval for Multiple Neuropsychiatric Indications

On March 18, 2022, the CDE website showed that Risperidone Oral Soluble Film from Qilu Pharmaceutical obtained clinical trial implied permission. This medicine is suitable for schizophrenia in adults and adolescents aged 13-17. For patients who respond effectively to acute treatment, this product can continue to exert its clinical efficacy during maintenance treatment; manic episodes of bipolar disorder in adults and children and adolescents aged 10-17; irritability associated with autism in children and adolescents aged 5-17; persistent aggression or other disruptive behaviors associated with intellectual disability or mental retardation and conduct disorders in children and adolescents aged 5-17.